Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-24
2009-06-23
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S177000, C546S178000
Reexamination Certificate
active
07550482
ABSTRACT:
The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
REFERENCES:
patent: 6133303 (2000-10-01), Bikker et al.
patent: 6265422 (2001-07-01), Bikker et al.
patent: 6472408 (2002-10-01), Carlier et al.
patent: 6528535 (2003-03-01), Bikker et al.
patent: 2001572 (1971-07-01), None
patent: 2449030 (1976-05-01), None
patent: 2287224 (1976-05-01), None
patent: WO 88/02251 (1988-04-01), None
patent: WO 02/28837 (2002-04-01), None
patent: WO 03/082350 (2003-10-01), None
International Search Report for International Application No. PCT/GB2005/00717, Sep. 16, 2005.
Dostenko,et al.,Russ. Chem. Bull., Int. Ed., 2002, 51, 1556-1561.
Pitts, et al.,Biorg. Med. Chem. Lett., 1998, 8, 307-312.
Schroeder, et al.,Eur. J. Med. Chem.—Chimica Therapeutica, 1979, 14, 309-315.
Shanazarov, et al.,Khimiya Geterotsiklicheskikh Soedinenii, 1991, 1, 86-92.
Haas, et al.,J. Heterocyclic Chem., 1981, 18, 619-622.
Schoepp, et al.,Neuropharmacology, 1999, 38, 1431-1476.
Roedig, et al.,Chem. Ber., 1958, 91, 330-339.
Roedig, et al.,Chem. Ber., 1960, 93, 2294-2300.
Stankevich et al.,Chem. Heterocycl. Compd.(Engl. Transl.), 1966, 2, 440-442; translated fromKhim. Geterotsikl. Soedin., 1966, 2, 583-585.
Gudrinietse et al.;Latv. PSR Zinat.Akad.Vestis Khim.Ser.; 1972; 622;Chem. Abstr.; 78; 29581m; 1973.
Yukhnevich et alLatv. PSR Zinat. Akad. Vestis Khim. Ser.; 1973; 699;Chem. Abstr.; 80; 82603n; 1974.
Junek, et al.,Z. Naturforsch. B, 1970, 25, 1423-1426.
Katsuri, et al.,Tetrahedron, 1975, 31, 527-531.
Albrecht, et al.,Arch. Pharm., 1975, 308, 588-594.
Roth, et al.,Arch. Pharm., 1977, 310, 48-55.
Bennett, et al.,J. Heterocycl. Chem., 1979, 16, 633-635.
Reimann, et al.,Arch. Pharm., 1985, 318, 871-878.
Reimann, et al.,Arch. Pharm., 1985, 318, 1105-1115.
Nitta, et al.,Bull. Chem. Soc. Jpn., 1990, 63, 932-934.
Murogova, et al.,Pharm.Chem.J.(Engl. Transl.), 1990, 24, 633-638.
Gatta, et al.,Heterocycles, 1992, 34, 991-1004.
Molina, et al.,Tetrahedron, 1995, 51, 1265-1276.
Fink, et al.;J. Med. Chem., 1995, 38, 3645-3651.
Miyabara, et al.,Heterocycles, 1999, 51, 983-988.
Pyrko,Chem. Heterocycl. Compd.(Engl. Transl.), 1999, 35, 688-694.
Fukumoto, et al.,J. Med. Chem.2002, 45, 3009-3021.
Okada, et al.,Heterocycles, 1997, 46, 129-132.
Lopez-Calle, et al.,Liebigs Ann. Org. Bioorg. Chem., 1996, 11, 1855-1866.
Carlier, et al.,Angew. Chem. Int. Ed. Eng., 2000, 112, 1845-1847.
Kantlehner, et al.,J. Prakt. Chem. / Chem.-Ztg., 1998, 340, 408-423.
International Search Report for International Application No. PCT/GB2005/003285, May 12, 2006.
Bruno et al.,Neuropharmacology, 2000, 39, 2223-30.
O'Leary et al.,Br. J. Pharmacol., 2000, 131, 1429-3.
Battaglia et al.,J. Neurosci.2001, 2, 2135-41.
Rao et al.,Neurosci. Lett., 2000, 293, 1-4.
Popoli et al.,J. Neurochem., 2004, 89, 1479-89.
Jaeschke et al.,Expert. Opin. Ther. Patents, 2008, 18, 123-142.
Feligioni et al.,J. Neurosci., 2003, 23, 6810-8.
Cowen, et al.,J. Pharmacol. Exp. Ther., 2005, 315, 590-600.
Vengeliene, et al.,Neuropharmacology, 2005, 48, 822-829.
Bachteler, et al.,Neuropsychopharmacology, 2005, 30, 1104-1110.
Aronica et al.,Neuroscience, 2001, 105, 509-20.
Ma, et al.,Neuroscience, 2006, 143, 95-104.
Shi et al.,J. Pharmacol. Exp. Ther., 2003 305, 131-42.
Bruno et al.,J. Cereb. Blood Flow Metab., 2001, 21, 1013-33.
Oka, et al.,Acta Neuropathol., 1999, 97, 275-278.
Balschun, et al.,Neuroscience, 2006, 142, 691-702.
Liu, et al.,J. Neurochem., 2005, 95, 1363-72.
Aaononsen, et al.,J. Pharmacol. Exp. Ther., 1999, 248, 1034-1038.
Spooren, et al.,Eur. J. Pharmacol., 2000, 406, 403-10.
Schultz, et al.,Neuropharmacology, 2001, 41, 1-7.
Tatarczynska, et al.,Br. J. Pharmacol., 2001, 132, 1423-30.
Spooren, et al.,Eur. J. Pharmacol., 2002, 435, 161-70.
Brodkin, et al.,Pharmacol. Biochem. Behav., 2002, 73, 359-66.
Cosford, et al.,J. Med. Chem., 2003, 46, 204-6.
Pietraszek, et al.,Eur. J. Pharmacol., 2005, 514, 25-34.
Gravius, et al.,Neuropharmacology, 2006, 51, 1146-1155.
Varty, et al.,Psychopharmacology(Berl), 2005, 179, 207-17.
Ballard, et al.,Psychopharmacology(Berl), 2005, 179, 218-29.
Huber et al.,Proc Natl Acad Sci USA, 2002, 99, 7746-50.
Kenny, et al.,An. N Y Acad Sci, 2003, 1003, 415-418.
Chiamulera et al.,Nat Neurosci, 2001, 4, 873-4.
Belozertseva, et al.,Eur. Neuropsychopharmacol., 2007, 17, 172-179.
Palucha, et al.,Pharmacol. Biochem. Behav., 2005, 81, 901-6.
Li, et al.,J. Pharmacol. Exp. Ther., 2006, 319, 254-9.
Pilc, et al.,Neuropharmacology, 2002, 43, 181-7.
Storto, et al.,Mol. Pharmacol., 2006, 69, 1234-1241.
Tizzano, et al.,Neuropharmacology, 1995, 34, 1063-1067.
Camon, et al.,J. Neurosci. Res., 1998, 51, 339-348.
Barton, et al.,Epilepsy Res., 2003, 56, 17-26.
Chapman, et al.,Neuropharmacology, 2000, 39, 1567-1574.
Frisby, et al.,Gastroenterology, 2005, 129, 995-1004.
Jensen, et al.,Eur. J. Pharmacol., 2005, 519, 154-7.
Frati, et al.,J Cell Physiol, 2000, 183, 364-72.
Aronica, et al.,Eur. J. Neurosci., 2003, 17, 2106-18.
Ye, et al.,Cancer Res, 1999, 59, 4383-9.
Albasanz, et al.,Eur. J. Pharmacol., 1997, 326, 85-91.
Park, et al.,Oncol Rep, 2007, 17, 81-7.
Movsesyan et al.,J. Pharmacol. Exp. Ther., 2001, 296, 41-7.
Lea et al.,Pharmacol. Biochem. Behav., 2002, 73, 287-98.
Gong et al.,J. Neurotrauma, 1999, 16, 893-902.
Llansola et al.,Neuroscience, 2005, 133, 185-91.
Canales et al.,Neurobiol Dis, 2003, 14, 380-90.
Orlando, et al.,Neurosci. Lett., 1995, 202, 109-12.
Addex—http://www.addexpharma.com/press-releases-old
ews-releases/20-april-2007/.
Popik, et al.,Neuropharmacology, 2002, 43, 1210-7.
Palucha et al.,Pol. J. Pharmacol., 2004, 56, 863-6.
Kotlinska, et al.,Eur. J. Pharmacol., 2007, 558, 113-8.
Kozela, et al.,Psychopharmacology(Berl), 2003, 165, 245-51.
Narita, et al.,J. Neurochem., 2005, 94, 1297-305.
Geurts et al.,Brain, 2003, 126, 1755-66.
Paterson, et al.,Psychopharmacology(Berl), 2005, 179, 255-61.
Bespalov, et al.,Neuropharmacology, 2005, 49 Suppl, 167-178.
Bisaga et al.,Eur. Neuropsychopharmacol., 2008, published online #42677.
Bradbury, et al.,J. Pharmacol. Exp. Ther., 2005, 313, 395-402.
Karim, et al.,J. Neurosci., 2001, 21, 3771-9.
Urban, et al.,Neuropharmacology, 2003, 44, 983-93.
Fisher, et al.,Pharmacol. Biochem. Behav., 2002, 73, 411-8.
Sevostianova, et al.,Neuropharmacology, 2006, 51, 623-630.
Hudson, et al.,J. Neurosci., 2002, 22, 2660-8.
Mills, et al.,J. Neurotrauma, 2002, 19, 23-42.
Walker, et al.,Neuropharmacology, 2001, 40, 1-9.
Walker, et al.,Neuropharmacology, 2001, 40, 10-9.
Ossowska, et al.,Neuropharmacology, 2001, 41, 413-20.
Ossowska, et al.Neuropharmacology, 2005, 49, 447-455.
Breysse, et al.,J. Neurosci., 2002, 22, 5669-78.
Breysse, et al.,J. Neurosci., 2003, 23, 8302-9.
Turle-Lorenzo, et al.,Psychopharmacology(Berl), 2005, 179, 117-127.
Golembiowska, et al.,Neuropharmacology, 2003, 45, 484-492.
Battaglia, et al.,J. Neurosci., 2002, 22, 2135-41.
Armentero, et al.,Neurobiol Dis, 2006, 22, 1-9.
Dekundy, et al.,Brain Res. Bull., 2006, 69, 318-326.
Mela, et al.,J. Neurochem., 2007, 101, 483-97.
Kinney, et al.,J. Pharmacol. Exp. Ther., 2005, 313, 199-206.
Mills, et al.,J. Neurochem., 2001, 79, 835-48.
Szydlowska, et al.,Eur. J. Pharmacol., 2007, 554, 18-29.
Danysz Wojciech
Henrich Markus
Jatzke Claudia
Jaunzeme Ieva
Jirgensons Aigars
Hueschen and Sage
Merz Pharma GmbH & Co. KGAA
Seaman D. Margaret
LandOfFree
Tetrahydroquinolones and their use as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroquinolones and their use as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroquinolones and their use as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147639